Sort

Search

01/09/2024 Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study
Bobes, A, Tormo, M, Diaz-Beya, M, Beneit, P, Botella, C, Moreno, AF, Mayol, AS, Sangerman, MA, Bermejo, AY, Amigo, MD, Labrador, J, Guinon, AG, Garrido, A, Serrano, J, Polo, SV, Fortes, MG, Sayas, MJ, Bergua, JM, Olave, MT, Vall-Llovera, F, Bargay, J, Sanchez, MP, Boyero, RG, Diaz-Lopez, A, de la Fuente, A. Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: "Real-Life" Data Versus the RATIFY Study. Clinical Lymphoma Myeloma & Leukemia. 2024; 24DOI:. PMID:. IF:2.700(Q2/4D).
01/09/2024 Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Kirkegaard-Biosca, C, del Barrio-Tofiño, E, Villamarín, M, Larrosa, N, Campany, D, González-López, JJ, Ferrer, R, Viñado, B, Doménech, L, Sellarès-Nadal, J, Escolà-Vergé, L, Fernández-Hidalgo, N, Los-Arcos, I. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics-Basel. 2024; 13(9)DOI:10.3390/antibiotics13090874. PMID:39335047. IF:4.600(Q1/2D).
01/09/2024 Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles
Parladé, E, García-Leon, A, Voltà-Durán, E, Unzueta, U, Mangues, R, Casanova, I, Villaverde, A, Váquez, E. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2024; 202DOI:10.1016/j.ejpb.2024.114410. PMID:39004320. IF:4.300(Q1/2D).
01/09/2024 Overview of Thigh and Leg Anatomical and Sonographic Landmarks in Rheumatic Patients
Balius, R, Pedret, C, Estrada-Alarcón, P, Corominas, H. Overview of Thigh and Leg Anatomical and Sonographic Landmarks in Rheumatic Patients. European Journal Of Rheumatology. 2024; 11DOI:10.5152/eurjrheum.2022.21131. PMID:36052637. IF:(Q/D).